Effect of bunazosin on platelet aggregation in essential hypertension.
スポンサーリンク
概要
- 論文の詳細を見る
The purpose of the present study in to clarify the effect of bunazosin on platelet aggregation in the patients with essential hypertension.In vitro, the effects of 10-3-10-5M bunazosin on platelet aggregations induced by ADP, epinephrine and A23187 were studied in untreated patients with essential hypertension. The concentration of 10-3-10-4M bunazosin inhibited the platelet aggregations.Before this oral administration of bunazosin study, the patients were treated with other antihypertensive drugs for 10±7 (M±SD) weeks. Platelet aggregation (Born's method) induced by 4.6μM ADP and 5.0μM epinephrine and whole blood aggregation (Impedance method) induced by 10μM ADP and 5.0μg/ml collagen were measured in 14 patients with essential hypertension before and after administration of 1.5mg/day or 3.0mg/day for 6±4 (M±SD) weeks. Blood pressure and heart rate were measured before and after administration of bunazosin. Platelet aggregation induced by both 4.6μM ADP and 5.0μM epinephrine had a tendency to decrease and whole blood aggregation induced by both 10μM ADP and 5.0μg/ml collagen was significantly decreased (p<0.05) after administration of bunazosin. Heart rate and systolic blood pressure were not significantly changed after administration of bunazosin in the patients treated with other drugs. On the other hand, diastolic blood pressure was significantly decreased (p<0.05) after administration of bunazosin in the same patients.The present results suggest that the inhibitory effect of bunazosin on platelet aggregation may be not due to the block of α2 receptor but the inhibition of cytoplasmic calcium increase relating to the platelet activation in essential hypertension.
- 一般社団法人 日本血栓止血学会の論文
一般社団法人 日本血栓止血学会 | 論文
- 日本人のＡＤＡＭＴＳ１３
- Infection of specific strains of Streptococcus mutans exacerbated intracerebral hemorrhage
- Transcriptional regulation of megakaryopoiesis and thrombopoiesis
- 新規血小板活性化受容体ＣＬＥＣ－２ その発見から今後の展望まで:その発見から今後の展望まで
- １．臨床血栓止血学オーバービュー